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Abstract
Background: Mixed adeno-neuroendocrine carcinoma (MANEC) of the biliary tract is rare with only a few reported
cases. Consequently, knowledge about their pathogenesis, histopathological characteristics and outcomes is sparce.
Case presentation: A 53-year old man presented with epigastric pain on a background of excessive alcohol
consumption. Contrast-enhanced computed tomography imaging of the liver revealed a central enhancing mass
located at the bifurcation of right anterior and posterior portal veins. Magnetic resonance imaging demonstrated
intrahepatic biliary duct dilatation distal to the mass. The patient underwent a right lobe hepatectomy and excision of
the extrahepatic biliary tree with formation of a hepaticojejunostomy. Histopathological finding of the specimen
revealed an intraductal tumour with predominant neuroendocrine immunohistochemical phenotype and infiltration
into nearby tissue. An element of glandular differentiation on immunohistochemistry confirmed the lesion as MANEC.
Conclusions: We present the first reported histopathological case of a MANEC arising from the intrahepatic bile ducts.
This report aims to review what is known about primary neuroendocrine and mixed adeno-neuroendocrine carcinoma
of the bile ducts, particularly in comparison to other types of biliary and hepatic tumours.
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Background
Malignancies affecting the extrahepatic bile duct are
rare, accounting for around 0.1–0.2 % of all cancer diag-
noses [1]. Of these cholangiocarcinoma is the common-
est cause, with adenocarcinoma making up around 80 %
of cases and other subtypes occurring much less
frequently [2]. Rarely biliary ductal tumours with neuro-
endocrine differentiation arise within the extrahepatic
bile ducts [3, 4]. Initial presentation may be associated
with features of local disease (biliary colic, painless jaun-
dice) or, occasionally, as a result of production of active
hormones.
According to the latest World Health Organisation
(WHO) classification system [5] biliary tract neuroendo-
crine tumours (BNET) are classified into neuroendocrine
tumours (NET), neuroendocrine carcinomas (NEC), and
mixed adeno-neuroendocrine carcinomas (MANEC).
MANEC is a subtype that shows characteristics of both
glandular and endocrine differentiation. MANEC of the
biliary ductal system are extremely rare, with only a
handful of published cases to-date [6, 7]. To date there
have been no published cases of MANEC derived from
the intrahepatic biliary ductal system. As a result little is
known about their pathogenesis and outcomes.
We report a case of MANEC of the intrahepatic bile
duct. Our aims are to describe its clinical presentation,
and the detailed immunophenotypic characteristics of
this tumour. Despite the paucity of cases in the litera-
ture, another objective is to compare the clinicopatho-
logic characteristics of various biliary tumours, and
predict outcomes of MANEC in biliary tumours.
Case presentation
Case history
A 53-year old man presented to his local district general
hospital with epigastric pain. Relevant past medical his-
tory includes type 2 diabetes mellitus, and a history of
excessive alcohol consumption of 44 units/week.
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The patient underwent an abdominal dual-phase con-
trasted computed tomography (CT) scan. In addition to
background liver steatosis and right liver atrophy, a central
mass was identified at the bifurcation of the right anterior
and posterior portal vein. The lesion was enhanced during
the arterial phase, and mild contrast washout at the portal
venous phase, suggestive of possible hepatocellular carcin-
oma (HCC) (Fig. 1a and b). The mass had increased in
size as compared to previous imaging. Subsequent mag-
netic resonance imaging (MRI) liver confirmed the same
mass in the right lobe with peripheral biliary ductal dilata-
tion. This then raised the possibility of a clinical diagnosis
of intrahepatic cholangiocarcinoma (Fig. 2a–e).
Preoperative bilirubin was 15 μmol/L (normal range: 4–
22 μmol/L), alkaline phosphatase was 110U/L (42–98U/L)
and aspartate transaminase was 39 IU/L (6–34 IU/L).
Alpha-Feto Protein (AFP) and carbohydrate antigen 19–9
(CA19-9) were 3.7kU/ml (<4kU/ml) and 7 (<33kU/L)
respectively.
This patient was then referred to our tertiary hepato-
pancreato-biliary centre for further management. Having
discussed this case in our multi-disciplinary meeting, fluor-
odeoxyglucose—positron emission tomography (FDG-
PET) CT scan was performed and excluded extrahepatic
metastasis. No FDG uptake was demonstrated within the
lesion as compared to the background liver parenchyma.
The patient was listed for surgical resection with cura-
tive intent. Right lobe hepatectomy and excision of the
extrahepatic biliary tree with the reconstruction of a
hepaticojejunostomy was performed. There were no
postoperative complications. Patient made a good post-
operative recovery and was subsequently discharged
home. 68Ga-DOTA-conjugated peptide PET scan com-
pleted 4 weeks post-operation did not demonstrate any
evidence of residual disease.
Histology and immunohistochemistry
A 20 mm diameter friable, greyish and pale tumor occu-
pied the lumen of the right hepatic duct and infiltrated
into the surrounding liver and hilar adipose tissue. The
background liver appeared yellowish with vague accentu-
ation of the lobular architecture.
At light macroscopy (Fig. 3a and b), approximately half
of the tumour mass formed an intraductal growth, with
the rest of the tumour infiltrating into periductal fibro-
vascular tissue and local liver parenchyma. Both the
intraductal and periductal infiltrative aspects were com-
posed of large sheets of relatively monomorphic cells
mixed with a rhabdoid or plasmacytoid appearance. Nu-
clei were generally round and regular and often showed
a “salt-and-pepper” appearance with focally increased
and dense chromatin. Immunohistochemistry in this cell
population stained strongly and diffusely for synaptophy-
sin (DAKO, M0776, 1:100) (Fig. 4a–b) and chromogra-
nin (DAKO, 1:100) (Fig. 4c–d). The proliferative rate
estimated with immunohistochemical analysis for Ki67
(MIB-1, DAKO, M0701, 1:100) was up to 8 % and up to
three mitotic figures were present in 50 HPF (Fig. 5).
A minor component of the cell population (estimated
to be around 30 %) showed a signet ring appearance
with clarification of the cytoplasm suggestive of intracel-
lular mucin (Fig. 6), which stained weakly with alcian-
blue-dPAS and showed focal acinar formation with
intraluminal mucin secretion (Fig. 7). With the limita-
tion of single epitope immunohistochemistry on serial
sections this cell population appeared to retain the ex-
pression of chromogranin and synaptophysin. This also
showed cytoplasmic or membranous expression of
MUC-1, (Fig. 8) (Abcam, Ab696-250, 1:100) predomin-
antly in the deeper aspect of the tumour, but did not
stain for MUC-2 (Novocastra, NCL MUC2, 1:100),
MUC5 (Novocastra, NCL MUC5, 1:100) or MUC-6
(Novocastra, NCL MUC6, 1:100). There was weak and
diffuse nuclear staining for CDX2 (Leica Bond RTU,
PA0535) throughout the tumour. Staining for CA19.9
(Leica RTU, PA 0424) highlighted the superficial compo-
nent of the intraductal growing tumor, in keeping with
residual biliary epithelium (Fig. 9). The background
Fig. 1 Dual phase abdominal contrast CT scan. Tumour at the bifurcation of the right anterior and posterior portal vein (arrow). Enhancement of
lesion during arterial phase (a), with mild contrast washout in portal venous phase (b). Liver shows background steatosis
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biliary epithelium did not reveal dysplasia or metaplastic
changes. Hep-Par1 staining of tumour was negative
(Fig. 10).
The background liver showed steatohepatitis, mainly
macrovesicular, affecting around 30 % of the hepatocytes
associated with a mild bridging fibrosis.
Conclusions
We present a rare case of intrahepatic biliary MANEC
and highlight the difficulty in establishing a pre-
operative diagnosis [8]. The differential diagnoses in this
case include intrahepatic cholangiocarcinoma, hepato-
cellular carcinoma and intrahepatic neuroendocrine car-
cinoma (Table 1 for clinicopathological comparison).
Cholangiocarcinoma occur most frequently in the hilar
region, at the confluence of the right and left hepatic
ducts. Those involving only the intrahepatic ducts are less
frequent, 8 % of all cholangiocarcinomas in one large
retrospective study [9]. The pattern of tumour growth and
its anatomical location mean that obstructive jaundice is a
late feature and tumour size tends to be larger with local
infiltration, as occurred in our case [9–11]. Blood or bile
testing for tumour markers such as CA19-9 and carci-
noembryonic antigen (CEA), are often of limited diagnos-
tic utility in isolation as both markers lack sensitivity and
specificity, as was evident in this case [12–14].
Mass-forming intrahepatic cholangiocarcinoma may
be difficult to differentiate from HCC on imaging. Dual-
phase contrasted CT is frequently a useful tool in differ-
entiating these pathologies with their characteristic
radiological findings. Cholangiocarcinomas are typically
hypo- or iso-attenuating relative to normal liver paren-
chyma at both arterial and portal venous phases, with
enhancement only in the delayed phase [8, 15]. This
finding reflects the hypovascular desmoplastic compos-
ition of cholangiocarcinoma. HCC on the other hand are
more hypervascular and tend to show arterial phase en-
hancement with portal venous phase washout. The le-
sion in this case was unusual as contrast CT imaging
showed arterial enhancement with mild washout at por-
tal venous phase suggestive of HCC, yet the MRI liver
demonstrated peripheral biliary obstruction, which is
Fig. 2 MRCP. Arterial phase demonstrating enhancement of tumour (arrow) (a), with images at 120 s post-contrast demonstrating washout of
contrast (arrow) (b), and successive axial images at 10 min post-contrast showing dilatation of interlobular bile ducts (arrowhead) (c, d, e)
Fig. 3 Low magnification view of intraductal (a) and periductal invasive component (b). H&E 20×
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more in keeping with a bile duct neoplasm. One large
retrospective study demonstrated that a significant pro-
portion of mass-forming intrahepatic cholangiocarcino-
mas had arterial enhancement on dual-phase CT [16].
BNET are very rare and represent less than 0.3 % of all
NET [3, 7]. They were first described in 1959, with only
150 cases published since then. The majority of these tu-
mours are located in the extrahepatic biliary tracts, with
smaller numbers originating at the bifurcation of the ex-
trahepatic biliary tree [3, 7, 17]. In clinical practice, these
lesions are difficult to diagnose and to distinguish from
cholangiocarcinoma preoperatively. Certain clinical fea-
tures can be useful in distinguishing one from the others.
For instance, BNET tend to affect younger patients, whilst
aggressive local invasion and distant metastatic disease is
seen more frequently in adenocarcinoma. A pre-operative
diagnosis can be made by examining brush cytology [18]
or detecting raised serum tumour markers [7], though
these methods have high false negative rates. A more pre-
cise pre-operative diagnostic technique is the use of spy-
glass endoscopy to obtain tissue biopsy from the lesion of
the biliary ductal system, though availability of this investi-
gative modality is often limited. Most of the time, surgical
resection is the treatment of choice in the first instance,
particularly when the lesion is deemed resectable on im-
aging, with a final diagnosis made following histopatho-
logical examination of the resected specimen. Pure BNET
show typical histological features of NET and may show
production of hormones, including somatostatin, sero-
tonin and gastrin [7]. Somatostatin analogues such as
octreotide, have been shown in clinical trials to be effica-
cious in improving symptoms and reducing tumour
growth [19]. Prognostic data for BNET are limited due to
their rarity. According to the most recent WHO
Fig. 4 Intraductal component showing strong and diffuse staining for synaptophysin (a and b) and chromogranin (c and d)
Fig. 5 Ki67 analysis estimated to be up to 8 % with up to three mitotic figures present in 50 HPF
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classification, they should be graded as conventional NET
taking into account in particular mitotic activity and Ki67
proliferative index [5, 20]: G1: mitotic count <2 HPF and/
or Ki67 index <2 %; G2: mitotic count 2–20 per 10 HPF
and/or Ki67 index 3–20 % and G3: mitotic count >20 per
10 HPF and/or Ki67 index >20 %. Overall outcomes ap-
pear to be better than in other types of biliary tract
malignancies.
Our case differs from conventional BNET and cholan-
giocarcinoma due to the mixed but tightly intermingled
neoplastic components on histological examination. The
bulk of the mass is represented by a moderately differen-
tiated NET, which stains diffusely for chromogranin and
synaptophysin. A minor cell population scattered
throughout the tumor and more prominently in its deep
aspect closer to the nearby liver parenchyma is com-
posed of cells with signet ring morphology. These cells
highlight well with Alcian blue/periodic acid-Schiff
(ALCIAN-PAS) and MUC1 staining, demonstrating acid
mucus production by these cells and providing support
to divergent glandular differentiation. This dual pheno-
type fits with the category of biliary MANEC and resem-
bles the case described by Harada [6] with the
adenocarcinomatous component found at the peripheral.
Biliary MANEC is exceedingly rare with only a few
cases published in the literature [21–26]. In one series of
hepatobiliary MANEC, only 9 cases were identified as
MANEC [6]. Two of these cases were categorised as
hepatic hilar MANEC, with the rest originating from
gallbladder and extrahepatic bile ducts. To date and to
our knowledge there have been no published cases of
MANEC originating from intrahepatic bile ducts. Biliary
MANEC have a phenotype that morphologically resem-
bles both adenocarcinoma and NEC. According to the
updated WHO classification, it was suggested that to be
classified as MANEC, at least 30 % of the main lesion
excluding any broad invasive area had to be made up of
Fig. 6 High magnification view of part of the lesion showing
clarification of the cytoplasm and signet ring morphology. H&E 400×
Fig. 7 Alcian blue diastase PAS. Tumour cells with signet ring
morphology showing weak cytoplasmic staining. 400×
Fig. 8 Numerous tumour cells in the areas showing signet ring
morphology stain for MUC-1. 30×
Fig. 9 CA19.9 staining highlights the superficial component of the
intraductal-growing tumor, most likely residual biliary epithelium
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each component [27]. Harada et al. found that the
adenocarcinoma components were predominantly lo-
cated on the surface of the tumours, whilst the neuroen-
docrine components were found deeper and associated
more often with stromal, vascular and lymphatic inva-
sion [6]. Our case is similar because the glandular com-
ponent was more pronounced at the peripheral
intraductal part of the tumour; whereas the infiltrating
component was mainly moderately differentiated (G2)
neuroendocrine (Ki67 up to 8 %). Nonetheless, the def-
inition of malignancy in this peculiar category of tu-
mours is still not well established [5].
As with Harada et al. [6], the proliferative index in our
case was higher in the neuroendocrine component com-
pared with the adenocarcinomatous population, suggest-
ing that neuroendocrine is the population upon which
prognosis depends.
Additional histopathological diagnoses to be consid-
ered in mixed differentiated intrahepatic tumours in-
clude intraductal papillary neoplasms (IPMN) and HCC
Fig. 10 Hep-Par1 staining showing negative hepatocellular tumour
differentiation, with normal adjacent liver parenchymal staining
(top right)
Table 1 Comparison of clinical, pathological and histological features of intrahepatic carcinomas






Liver parenchyma Perihilar and extrahepatic,
rarely intrahepatic [9, 30]
Extrahepatic biliary tract Very rare, perihilar and
extrahepatic bile ducts [6]




Raised hepatitic enzymes Intrahepatic—typically raised
ALP and GGT, normal or
mildly elevated bilirubin
Raised ALP and GGT As cholangiocarcinoma
and BNET
Tumour markers—AFP [31] Tumour markers CA19-9 and






phase with portal venous




liver on dual-phase contrast






Increased T2 intensity on MRI Evidence of biliary tract
obstruction with proximal




hepatocytes. It can have
different type of architecture




variable sized tubular structures,
formation of acini or
micropapillary structures. The
intraductal growth in the
extrahepatic biliary tree can
present as BilIN or IPNB [32]. It
does not express chromogranin
and synaptophysin extensively
These tumours are composed of
cells superimposable to those of
gut and pancreas endocrine cell
and show diffuse positivity for
Chromogranin A and
synaptophysin without any other
differentiation [5]
Adenocarcinoma component
typically on tumour surface,
with stromal, vascular and local







Prognosis Highly variable dependent
on staging, grading, presence
or absence of cirrhosis [33]
Better outcomes in intrahepatic
tumours For R0-resected
intrahepatic tumours—median
survival 80 months, 5-year
survival 63 % [9]
Dependent on grade (mitotic





Appears to have better long-term
survival rate compared with other
biliary tract malignancies [34]
45 month survival in one
case [29]
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with neuroendocrine differentiation. IPMN are a precur-
sor lesion that may rarely show neuroendocrine differen-
tiation [7], but are characterized by protruding papillae
covered by dysplastic epithelium with mucin secretion.
In our case, there was an abrupt passage from the nor-
mal bile duct epithelium to the neoplastic mass without
any evidence of preneoplastic lesion. Moreover, the epi-
thelial marker CA19.9 and MUC1 stained only part of
the tumour suggesting that there are two separate and
discrete albeit mixed components. MANEC is therefore
more likely to be derived from the adenocarcinomatous
cells, rather than from neuroendocrine populations [21].
HCC with neuroendocrine differentiation has been anec-
dotally reported and remains unrecognised in the most
recent WHO classification system. Our tumour did not
resemble HCC morphologically, and Hep-Par1 staining
was negative [28].
With only a paucity of cases, it is difficult to fully as-
certain the long-term prognosis of biliary MANEC.
There had been a report of 45-month survival in one pa-
tient who underwent surgical treatment alone [29].
However, that patient had a composite adenocarcinoma
(40 %) and NEC (60 %) of the common bile duct. Al-
though the location of the tumour is distinguishably dif-
ferent from our case, both cases had low proliferative
fractions (<10 % Ki-67-positive tumour cells), which
have been shown to provide significant prognostic infor-
mation [20].
In summary, we report an intraductal invasive neo-
plasm with divergent predominantly neuroendocrine dif-
ferentiation arising from the right intrahepatic biliary
duct in keeping with a biliary MANEC. To our know-
ledge, this is the first reported case of an intrahepatic
biliary MANEC, with the few previously reported cases
affecting the extrahepatic biliary ductal system. On-
going research is necessary to increase our understand-
ing of the pathogenesis of this rare disease.
Consent
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